JANONE INC (JAN) Stock Price & Overview

NASDAQ:JAN • US47089W1045

Current stock price

2.23 USD
+0.09 (+4.21%)
Last:

The current stock price of JAN is 2.23 USD. Today JAN is up by 4.21%. In the past month the price decreased by -13.23%. In the past year, price increased by 120.79%.

JAN Key Statistics

52-Week Range0.2204 - 5.26
Current JAN stock price positioned within its 52-week range.
1-Month Range1.72 - 2.67
Current JAN stock price positioned within its 1-month range.
Market Cap
26.024M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-3.97
Dividend Yield
N/A

JAN Stock Performance

Today
+4.21%
1 Week
+6.19%
1 Month
-13.23%
3 Months
-24.41%
Longer-term
6 Months +291.23%
1 Year +120.79%
2 Years -19.20%
3 Years -69.41%
5 Years N/A
10 Years N/A

JAN Stock Chart

JANONE INC / JAN Daily stock chart

JAN Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to JAN. When comparing the yearly performance of all stocks, JAN is one of the better performing stocks in the market, outperforming 94.9% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

JAN Earnings

Next Earnings DateAug 15, 2024
Last Earnings DateMay 22, 2024
PeriodQ1 / 2024
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

JAN Forecast & Estimates


Analysts
Analysts0
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

JAN Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

JAN Financial Highlights

Over the last trailing twelve months JAN reported a non-GAAP Earnings per Share(EPS) of -3.97. The EPS decreased by -163.18% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-20.04M
Industry RankSector Rank
PM (TTM) N/A
ROA -107.89%
ROE -262.72%
Debt/Equity 0.14
Chartmill High Growth Momentum
EPS Q2Q%-110.79%
Sales Q2Q%N/A
EPS 1Y (TTM)-163.18%
Revenue 1Y (TTM)-100%

JAN Ownership

Ownership
Inst Owners5.8%
Shares11.67M
Float11.48M
Ins Owners1.88%
Short Float %N/A
Short RatioN/A

JAN Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
LLY ELI LILLY & CO28.18929.285B
JNJ JOHNSON & JOHNSON20.74582.039B
MRK MERCK & CO. INC.22.34285.833B
PFE PFIZER INC8.9151.141B
BMY BRISTOL-MYERS SQUIBB CO9.33120.315B
ZTS ZOETIS INC16.3448.807B
RPRX ROYALTY PHARMA PLC- CL A8.8326.334B
VTRS VIATRIS INC5.3915.555B
ELAN ELANCO ANIMAL HEALTH INC21.8111.405B
AXSM AXSOME THERAPEUTICS INC N/A7.983B
BLTE BELITE BIO INC - ADR N/A6.157B
TERN TERNS PHARMACEUTICALS INC N/A4.94B
LGND LIGAND PHARMACEUTICALS23.94.046B

About JAN

Company Profile

JAN logo image JanOne, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. The company is headquartered in Las Vegas, Nevada and currently employs 5 full-time employees. The company went IPO on 2006-02-22. Through its fintech activities, it provides blockchain-powered technologies to enable a migration to a new global financial paradigm for the trading, clearing, settlement, payment, and custodianship of digital instruments. Through its fintech subsidiaries, it offers two main platforms to its customers: ALT5 Pay and ALT5 Prime. ALT5 Pay is a cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay's checkout widgets and APIs. ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Through its biotech activities, it is developing solutions intended to help end the opioid crisis.

Company Info

IPO: 2006-02-22

JANONE INC

325 E Warm Springs Rd Ste 102

Las Vegas NEVADA 89119 US

CEO: Tony Isaac

Employees: 5

JAN Company Website

Phone: 17029975968

JANONE INC / JAN FAQ

Can you describe the business of JANONE INC?

JanOne, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. The company is headquartered in Las Vegas, Nevada and currently employs 5 full-time employees. The company went IPO on 2006-02-22. Through its fintech activities, it provides blockchain-powered technologies to enable a migration to a new global financial paradigm for the trading, clearing, settlement, payment, and custodianship of digital instruments. Through its fintech subsidiaries, it offers two main platforms to its customers: ALT5 Pay and ALT5 Prime. ALT5 Pay is a cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay's checkout widgets and APIs. ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Through its biotech activities, it is developing solutions intended to help end the opioid crisis.


What is the current price of JAN stock?

The current stock price of JAN is 2.23 USD. The price increased by 4.21% in the last trading session.


Does JANONE INC pay dividends?

JAN does not pay a dividend.


What is the ChartMill technical and fundamental rating of JAN stock?

JAN has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


What is JANONE INC worth?

JANONE INC (JAN) has a market capitalization of 26.02M USD. This makes JAN a Nano Cap stock.


When does JANONE INC (JAN) report earnings?

JANONE INC (JAN) will report earnings on 2024-08-15, after the market close.